Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ONCO-COMP

Financiado

Oncogenic competence during development – When, Where and Why?

Childhood cancers are believed to be rooted in aberrant development, a notion supported by their (i) generally low mutational burden, (ii) high prevalence of single (often epigenetic) driver events and (iii) occurrence during conf... ver más

31/08/2028

FUNDACIO PRIVADA P...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

FUNDACIO PRIVADA PER LA RECERCA I LA DOCENCIA... Otras actividades asociativas n.c.o.p. asociacion

TRL 4-5 | 50K€

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-01-12

ERC-2022-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

2 Participantes

FUNDACIO PRIVADA PER LA RECE...

1.50M€ | Lider

FUNDACIO INSTITUT DE RECERCA...

1.11M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-118241RA-I00 EL EPIGENOMA MALVADO DE LOS TUMORES RABDOIDES - DEFINIR PARA... 218K€ Cerrado

TargetSWItch Targeting SWI/SNF-related chromatin remodelling defects in s... 1M€ Cerrado

SAF2016-76758-R ESTUDIO MOLECULAR DE LOS MECANISMOS RESPONSABLES DEL PAPEL D... 145K€ Cerrado

RTI2018-096359-A-I00 ACTIVACION ONCOGENICA ESPORADICA DURANTE LA DIFERENCIACION N... 157K€ Cerrado

SAF2014-53526-R ONCOPROTEINAS MYC Y CTCF EN EL CONTROL TRANSCRIPCIONAL DE LA... 339K€ Cerrado

PID2020-117539GB-I00 CONEXIONES ENTRE LAS ALTERACIONES EN EL COMPLEJO REMODELADOR... 242K€ Cerrado

Duración del proyecto: 67 meses Fecha Inicio: 2023-01-12
Fecha Fin: 2028-08-31

Líder del proyecto

FUNDACIO PRIVADA PER LA RECERCA I LA DOCENCIA... Otras actividades asociativas n.c.o.p. asociacion

TRL 4-5 | 50K€

Presupuesto del proyecto 1M€

Descripción del proyecto Childhood cancers are believed to be rooted in aberrant development, a notion supported by their (i) generally low mutational burden, (ii) high prevalence of single (often epigenetic) driver events and (iii) occurrence during confined developmental periods. Yet, the exact origins of developmental tumours remain one of the principal enigmas of pediatric oncology. A prime example are malignant rhabdoid tumours (MRTs): they are astoundingly genomically simple but extremely deadly childhood cancers that arise almost exclusively in the first two years of life, and are driven by biallelic inactivation of the SWI/SNF chromatin remodelling complex subunit SMARCB1 (>95% of cases). We still do not know what determines oncogenic competence upon SMARCB1 loss. In particular we wonder: (1) What are the cell(s)-of-origin of rhabdoid tumours and what is their normal differentiation potential? (2) What is the molecular framework that facilitates oncogenic transformation upon SMARCB1 loss? (3) What is the contribution of the niche (local and systemic) to the acquisition of oncogenic competence? And, considering the epigenetic nature of the oncogenic event, (4) is the oncogenic MRT state reversible, and how? To answer these questions, we will combine state-of-the-art lineage-barcoded single-cell genomics, spatial transcriptomics, single-cell resolution wholemount imaging, CRISPR/Cas9 and epigenomic approaches, as well as integrative computational analyses, using transgenic mouse, induced pluripotent stem cell and patient-derived xenograft rhabdoid tumour models. This project will provide fundamental insights into the cell autonomous and non-autonomous determinants of oncogenic competence upon SMARCB1 loss. Based on our findings we hope to unlock targeted treatments for MRT patients. Importantly, the conceptual and experimental framework we establish will open up new investigative opportunities for a multitude of developmental cancers.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores